ICON Plc

ICON Plc ICON is a global provider of outsourced clinical research development services to the pharmaceutical, biotechnology, and medical device industries.

We help our clients accelerate the development of life-saving drugs that improve patients' quality of life.

Laboratory careers are built on more than technical expertise.They require precision, collaboration, and a strong sense ...
21/04/2026

Laboratory careers are built on more than technical expertise.

They require precision, collaboration, and a strong sense of accountability to ensure every result meets the highest standards.

This Medical Laboratories Week, we are highlighting the core skills that power laboratory roles at ICON and support the delivery of high quality clinical research.

Which of these skills do you see in your own experience?

Reporting results with clarity and consistencyDecision makers require accessible, reproducible outputs. The whitepaper e...
21/04/2026

Reporting results with clarity and consistency

Decision makers require accessible, reproducible outputs. The whitepaper explains how evidence networks, forest plots, league tables and rankograms work together to communicate comparative effectiveness clearly across a treatment landscape. These visualisations support faster interpretation and more informed decision making.

Explore more insights: https://ow.ly/TTzc50YwbaZ

Parkinson’s disease (PD) is the fastest-growing neurological condition in the world, and recent estimates suggest that t...
21/04/2026

Parkinson’s disease (PD) is the fastest-growing neurological condition in the world, and recent estimates suggest that the number of people living with Parkinson’s will double to 25 million by the year 2050. Explore how ICON is working to improve drug development and advance treatments for and other movement disorders. https://ow.ly/6VYO50Yv7Jt

ICON is excited to sponsor RAPS Euro Convergence 2026, taking place 5–8 May in Lisbon. ICON are joining regulatory leade...
21/04/2026

ICON is excited to sponsor RAPS Euro Convergence 2026, taking place 5–8 May in Lisbon.

ICON are joining regulatory leaders at RAPS Euro Convergence 2026, taking place 5–8 May in Lisbon.
Drop by and meet Gabriel Bohl and Laurent Valentin at booth #21.

They will be on hand to discuss how ICON strengthens regulatory readiness and supports confident decision making across each stage of product development. They will share how our team helps organisations navigate evolving European and global requirements, streamline regulatory planning and address challenges with clarity and strategic insight.

Learn more about the event https://ow.ly/Ef6W50YEt9Q

What does your work mean to patients?At ICON, this question sits at the heart of what we do.This Medical Laboratories We...
20/04/2026

What does your work mean to patients?

At ICON, this question sits at the heart of what we do.

This Medical Laboratories Week, we asked members of our laboratory teams to share what their work means to them. Their responses reflect the precision, responsibility, and purpose that define laboratory science in clinical research.

Every sample represents a patient, a study, and the potential to advance treatment.

Take a moment to read their perspectives.

Which one resonates most with you?

Pediatric trials face unique complexity but selecting a fit for purpose HRQoL measure doesn’t have to. The FDA’s PFDD Gu...
20/04/2026

Pediatric trials face unique complexity but selecting a fit for purpose HRQoL measure doesn’t have to. The FDA’s PFDD Guidance emphasizes that historical use is not justification. Sponsors must demonstrate why an instrument is appropriate for their specific population and study decisions.

Our new blog applies a practical selection framework to the PedsQL™, highlighting why it often emerges as a strong option in global pediatric programs. https://ow.ly/V3zx50YBLmm

Join us on 6 May at OCT Europe in Barcelona. At 12:00pm in Stream C, Ankita Minhas will present “The global biotech sect...
20/04/2026

Join us on 6 May at OCT Europe in Barcelona. At 12:00pm in Stream C, Ankita Minhas will present “The global biotech sector: A CRO perspective”. Discover how rising scientific and operational complexity, AI‑driven innovation, and disciplined ex*****on are reshaping the global biotech landscape. Ankita will also share how integrated CRO partnerships are enabling faster, more predictable development for emerging and established biotech companies.

16th Annual Outsourcing in Clinical Trials Europe 2026 - Arena International. https://ow.ly/4GQA50YBCJO

ICON Biotech will participate in , the 13th Annual Clinical Trials in Oncology West Coast, taking place on 28–29 April ...
17/04/2026

ICON Biotech will participate in , the 13th Annual Clinical Trials in Oncology West Coast, taking place on 28–29 April 2026 in Burlingame, California.

The event brings together oncology and clinical research professionals to discuss the scientific, operational, and strategic considerations shaping oncology clinical development.

ICON Biotech supports biotechnology sponsors with oncology-focused clinical development services designed to align with program stage, scientific complexity, and operational priorities.

Through tailored engagement models and dedicated teams, ICON Biotech works with sponsors to support efficient trial ex*****on and informed development decisions.

Learn more here: https://ow.ly/Rqr650YwhqB

We’re honoured to receive the Best Clinical Trial Supplier Award: Site Innovation at the Asia‑Pacific Biopharma Excellen...
17/04/2026

We’re honoured to receive the Best Clinical Trial Supplier Award: Site Innovation at the Asia‑Pacific Biopharma Excellence Awards 2026 — our second consecutive win.

This recognition reflects the commitment of our APAC teams to accelerating clinical development and delivering meaningful impact for patients worldwide.

Read more about the award: https://ow.ly/PnkV50YKPu2

For long-term vaccine follow-up, traditional onsite studies and newer strategies, such as tokenisation, each have unique...
17/04/2026

For long-term vaccine follow-up, traditional onsite studies and newer strategies, such as tokenisation, each have unique advantages. Discover how the expected timeframe, type of data needed and study population can play a role in deciding on an approach to follow-up in our article. https://ow.ly/QNZG50YEsGO

Operationalising NMA in RThe paper provides a clear overview of how netmeta and multinma support high quality analyses.–...
16/04/2026

Operationalising NMA in R

The paper provides a clear overview of how netmeta and multinma support high quality analyses.
– Netmeta enables contrast based, frequentist NMA with automated network construction and heterogeneity assessment
– Multinma provides flexible, Bayesian modelling with support for complex evidence structures and covariate adjustments

These tools support transparent, reproducible workflows aligned with HTA expectations. Discover more insights: https://ow.ly/TTzc50YwbaZ

Proposed requirements for Mechanism of Action based PIPs are coming. Right now, they’re still developing. ICON can help ...
16/04/2026

Proposed requirements for Mechanism of Action based PIPs are coming. Right now, they’re still developing. ICON can help sponsors position to stay ahead of the curve and benefit from incentives while meeting pediatric obligations.

Learn more here: https://ow.ly/pf8B50XSUET

Address

South County Business Park, Leopardstown
Dublin
18

Opening Hours

Monday 8am - 5pm
Tuesday 8am - 5pm
Wednesday 8am - 5pm
Thursday 8am - 5pm
Friday 8am - 5pm

Telephone

+35312912000

Website

Alerts

Be the first to know and let us send you an email when ICON Plc posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to ICON Plc:

Shortcuts

Featured

Share

Category